• Zevalin Improves Survival of Non-Hodgkin’s Lymphoma Patients in Real-world Setting, Study Finds
  • As a Member of the Cancer Club, Coronavirus Is Not Fun
  • FDA Grants Orphan Drug Status to Umbralisib for Follicular Lymphoma
  • First Patient Treated in MB-106 CAR T-cell Trial Now Cancer Free, Mustang Says
  • CLR 131 Shows Anti-tumor Activity, Safety in Difficult-to-treat B-cell Lymphoma Trial
  • Tafasitamab Plus Revlimid Granted FDA Priority Review for Relapsed or Refractory DLBCL
  • The Paradox of Healing
  • Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare
  • Tipifarnib Granted FDA Fast Track Designation for T-cell Lymphomas
  • Tessa’s CD30 CAR T-cell Therapy for Lymphoma Granted RMAT Status by FDA
  • Corvus’ CPI-818 Shows Promising Early Results in T-cell Lymphomas, Data Finds
  • CAR NK Cells Demonstrate High Response Rate and Safety in Lymphoma and Leukemia, Early Trial Shows